NO initiates and maintains vasodilation through a cascade of biological events that culminate in the relaxation of smooth muscle cells that line arteries, veins, lymphatics. While somewhat complex, the sequence of biological events that are triggered by NO is described below:  Thomas Burke, Ph.D.   NO initiates and maintains vasodilation through …

To understand NO metabolism in diabetic patients we must first discuss the normal process of NO formation. NO is a gas that is also a short-lived, unstable free radical and, within seconds of production, must become stabilized. To do so, it reacts with one or more elements or biologic compounds, as …

Nitric Oxide Synthase (NOS) is the enzyme that generates NO from L-arginine as described in Part 1 of this series. However, the enzyme exists in three different forms called isoforms. Each isoform synthesizes NO but does so under different conditions. Often all three isoforms will be found in the same …

This is the first in a series of articles that relate specifically to nitric oxide (NO), a free radical gas that is a powerful regulator of circulation (It is an endogenous vasodilator.) and a neurotransmitter (It helps in the processing of nerve signals as they cross synapses.). L-arginine, one of …

This is an exciting week for many of our readers. As you receive this newsletter over 3,000 of the most recognized experts in Diabetes Care, CDE’s, will be gathering in Atlanta for the American Association of Diabetes Educator’s 36th Annual Meeting. This year there is a lot to talk about. …

2nd DPP-4 inhibitor gets FDA Approval Onglyza™ (saxagliptin) a new DPP-4 inhibitor similar to Januvia will give physicians another option in treating their patients with diabetes. See This Week’s Item #1.

New Insulin Patch gets FDA Approval A new mini tubeless insulin infusion patch will go on sale in the U.S.. See this week’s new product information and check out This Week’s Item #4.

Diabetes in Control is the first to present the Solo product information to the diabetes community.   The FDA approved the Solo MicroPump for sale in the US on July 28th, The Solo MicroPump will be the smallest, lightest, most discreet full-featured insulin pump in the market. In addition, it will offer …

Patients with Type 2 diabetes now have a new treatment option: saxagliptin, a dipeptidyl peptidase-4 inhibitor that stimulates the pancreas to create more insulin after meals.

Several risk factors may help identify factors linked to poor outcomes for bariatric surgery, according to the results of a study.